Bionano Genomics, Inc. (BNGO)
NASDAQ: BNGO · Real-Time Price · USD
3.880
-0.180 (-4.43%)
At close: Sep 12, 2025, 4:00 PM EDT
3.950
+0.070 (1.80%)
After-hours: Sep 12, 2025, 7:42 PM EDT
Bionano Genomics Revenue
Bionano Genomics had revenue of $6.73M in the quarter ending June 30, 2025, a decrease of -13.36%. This brings the company's revenue in the last twelve months to $27.43M, down -25.02% year-over-year. In the year 2024, Bionano Genomics had annual revenue of $30.78M, down -14.79%.
Revenue (ttm)
$27.43M
Revenue Growth
-25.02%
P/S Ratio
0.33
Revenue / Employee
$274,260
Employees
100
Market Cap
18.16M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 30.78M | -5.34M | -14.79% |
Dec 31, 2023 | 36.12M | 8.31M | 29.90% |
Dec 31, 2022 | 27.80M | 9.82M | 54.62% |
Dec 31, 2021 | 17.98M | 9.48M | 111.47% |
Dec 31, 2020 | 8.50M | -1.63M | -16.06% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BNGO News
- 19 days ago - Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress - GlobeNewsWire
- 5 weeks ago - Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL - GlobeNewsWire
- 5 weeks ago - Bionano to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 6 weeks ago - Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025 - GlobeNewsWire
- 4 months ago - Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders - GlobeNewsWire
- 4 months ago - Bionano Genomics, Inc. (BNGO) Q1 2025 Earnings Call Transcript - Seeking Alpha